1.428SEK-0.42%Mkt Cap: 28.80M SEKP/E: —Last update: 2026-06-01
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company's pipeline products include RMC-035, an intact therape…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap28.80M SEK
Enterprise Value-12.07M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-108.85M SEK
Revenue/Share—
Last Price1.428 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009973357
Valuation
P/E (Trailing)—
P/E (Forward)-0.18
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.71
EPS (TTM)-3.53
EPS (Forward)-8.06
52W Range
0.88102% of range27.00
52W High27.00 SEK
52W Low0.8810 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-267.90%
ROA-201.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.35M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-11.15%
Net Debt-40.99M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.13
Quick Ratio6.55
Book Value/Sh2.015 SEK
Cash/Share2.033 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateDec 15, 2023
Analyst Consensus
Rating—
Target (Mean)1.750 SEK
Target Range1.750 SEK – 1.750 SEK
# Analysts1
Ownership
Shares Out.20.17M
Float15.93M
Insiders28.67%
Institutions37.01%
Technical
SMA 501.265 (+12.9%)
SMA 2006.367 (-77.6%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)42.57K
Avg Vol (10d)17.62K
Technical Indicators
RSI (14)59.1
MACD0.0531
MACD Signal0.0271
MACD Hist.+0.0259
BB Upper1.563 SEK
BB Middle1.268 SEK
BB Lower0.9726 SEK
BB Width46.58%
ATR (14)0.1340 SEK
Vol Ratio (20d)0.31x